Psychedelic Treatments: Bringing Out the Truth

September 21, 2020 14:22:37

In a discussion with Charles Raison, Psych Congress co-chair and professor at the University of Wisconsin-Madison, Penn., psychedelics, when used as treatments were more than just finding another way to reduce a disease’s symptoms.

Andrew D. Penn is also a Psych Congress member and an associate clinical professor at the University of California. He explains that psychedelics would redefine psychiatry as the substances focused on healing. The field of psychiatry has tried to find a means to cure people, without success. Instead, the field has succeeded in reducing or rather, managing symptoms, which is not necessarily a bad thing. It helps improve individual’s functioning and decreases their suffering.

Psychedelic treatments on the other hand offer an opportunity to actually heal people by treating the root cause of the problem, rather than the symptoms that occur as the result of the problem. The psychedelics route also challenges researchers and individuals at large to redefine how we view the field of psychiatry. Currently, the field mostly focuses on improving an individual’s symptoms.

Penn stated that a decade ago, he had received a lot of skepticism with regards to the use of psychedelic substances as treatments in psychiatry. The doubts, he said, usually originate from a place of misunderstanding and misinformation concerning why and how the psychedelic substances are used in treatment.

He explained that induced sessions were not easy, as the individuals were actually dealing with their traumas. It was not just about getting high and having a good time. The sessions provided people with a way to go deep within themselves and seek out their root problems. The psychedelics helped them heal in a way that prescribed medications taken daily and improving symptoms would not.

He stated that therefore, it would be wrong to say that all drugs were equally hedonistic and dangerous.

Dr. Raison recounted the story of a patient who stopped taking antidepressants after using them for a long time because she had been experiencing feelings of dullness. However, a month after she stopped taking the antidepressants, signs of depression resurfaced. He explained that antidepressant did not help an individual heal. Instead, they made the individual ignore the problem, an ‘ignore it and it will go away’ scenario if you will.

On the other hand, the use of psychedelics as treatments in psychiatry offers patients the option of openly dealing with the main causes of their depression. To put it simply, it enables individuals to seek out the truths within them and confront those that plague them, those that prevent them from healing.

Psychedelics are going mainstream, with more and more researchers carrying out studies that showcase the many benefits that psychedelics possess. For instance, in clinical studies, psilocybin is being used to treat major depressive disorder as well as PTSD in veterans. MDMA is being used to treat PTSD and LSD is being used to help treat anxiety as well as depression. As you can clearly see, psychedelic-assisted therapy is on the rise and with psilocybin being designated as a “breakthrough therapy” by the FDA in 2019. It may not therefore be long before psychedelic treatments are an approved alternative source of treatment. The possibility of this future is what could be the wind beneath the wings of psychedelics companies like Cybin Corp.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.